Compare · NEOG vs ORKA
NEOG vs ORKA
Side-by-side comparison of Neogen Corporation (NEOG) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NEOG and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $3.32B, about 1.7x NEOG ($1.94B).
- Over the past year, NEOG is up 57.0% and ORKA is up 364.6% - ORKA leads by 307.6 points.
- ORKA has been more active in the news (9 items in the past 4 weeks vs 2 for NEOG).
- ORKA has more recent analyst coverage (11 ratings vs 5 for NEOG).
- Company
- Neogen Corporation
- Oruka Therapeutics Inc.
- Price
- $8.92-0.50%
- $55.01-5.93%
- Market cap
- $1.94B
- $3.32B
- 1M return
- -5.01%
- -19.85%
- 1Y return
- +57.04%
- +364.61%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1989
- News (4w)
- 2
- 9
- Recent ratings
- 5
- 11
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest NEOG
- SEC Form SD filed by Neogen Corporation
- Former Chief Legal Officer Rocklin Amy M exercised 35,183 shares at a strike of $9.29 and covered exercise/tax liability with 10,241 shares, increasing direct ownership by 44% to 82,182 units (SEC Form 4)
- Chief Accounting Officer Moylan John Patrick exercised 4,558 shares at a strike of $9.53 and covered exercise/tax liability with 1,568 shares, increasing direct ownership by 21% to 17,337 units (SEC Form 4)
- Chief Legal Officer Stacey Jennifer Evans was granted 39,349 shares (SEC Form 4)
- Neogen's Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
- Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Stacey Jennifer Evans
- SEC Form 10-Q filed by Neogen Corporation
- Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neogen Reports Third Quarter Fiscal Year 2026 Financial Results
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 7,833 shares at a strike of $28.80 and sold $607,806 worth of shares (10,290 units at $59.07) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 16,406 units (SEC Form 4)
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $432,935 worth of shares (7,000 units at $61.85) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma
- Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology